Disease relevance of MK 486

• Skin rash associated with Sinemet 25/100 [1].
• Unsuccessful treatment of severe pain from bone metastasis with Sinemet 25/100 [2].
• We related the laboratory findings to signs of sympathetic neurocirculatory failure (orthostatic hypotension and abnormal blood-pressure responses associated with the Valsalva maneuver), central neural degeneration, and responsiveness to treatment with levodopa-carbidopa (Sinemet) [3].
• Sinemet and the treatment of Parkinsonism [4].
• Sinemet is currently the most widely used drug for treating Parkinson's disease [5].

Psychiatry related information on MK 486

• However, 10 patients showed a slight decrease of this improvement after 6 months; 3 had to be put back on standard Sinemet because of hallucinations (1) or accentuation of dyskinesia and akinesia (2) [6].

High impact information on MK 486

• The interference across tasks improved in 87% of the patients with PD when tested after treatment with carbidopa/levodopa (Sinemet) [7].
• A double-blind comparison of levodopa, Madopa, and Sinemet in Parkinson disease [8].
• The effect of Sinemet CR on dyskinesias is often difficult to predict and, in individual patients, may depend on the temporal pattern of dyskinesias being experienced [9].
• Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies [10].
• Compared with the standard Sinemet group, Sinemet CR patients had more "on" time (mean 83% versus 62%, p less than 0.001), and had a lower prevalence of disabling chorea (p less than 0.007), dystonia (p less than 0.003) and sleep disruption (p less than 0.002) [11].

Chemical compound and disease context of MK 486

• Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa [11].
• Pergolide mesylate, a dopamine agonist, was studied as adjunctive therapy in a 6-month double-blind trial in 20 patients with Parkinson's disease who were achieving less than optimal response from Sinemet [12].
• Plasma and CSF concentrations of endogenous L-DOPA, catecholamines, and metabolites of monoamines were assayed in a patient with atypical phenylketonuria due to absent dihydropteridine reductase (DHPR), before and during treatment with folinic acid, Sinemet, and 5-hydroxytryptophan [13].
• Previous short-term studies have shown that the dopamine agonist pergolide improves control of Parkinson's disease when used in conjunction with carbidopa-levodopa (Sinemet) [14].
• An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate [15].

Biological context of MK 486

• Despite a strong relationship between reductions in levodopa AUC and reductions in Sinemet efficacy (r = 0.83, P less than 0.01), the average reduction in Sinemet's efficacy associated with ferrous sulphate did not achieve statistical significance (P = 0.055) [16].
• The effect of levodopa or levodopa-carbidopa (sinemet) on fracture healing [17].
• The kinetics of Sinemet CR are limited by rates of absorption (which depend on the dose administered), the conformation of the tablet, and daily variations in the patterns of gastric emptying (influenced by the presence or absence of food) [18].

Anatomical context of MK 486

• Therapeutic doses of Sinemet have no significant effect on thyroid function in euthyroid patients with Parkinson disease [19].
• Replacement of DA by chronic treatment with laevodopa (L-DOPA, administered as Sinemet) caused short-term improvements in activity and rearing behaviour, and abolished abnormal spontaneous hindlimb grooming [20].
• Peripheral nerve block extinguished the lower extremity rigidity in one patient, and two patients had a favorable response to Sinemet [21].
• The loss of dopamine was equivalent in the Sinemet and the bromocriptine treated animals (more than 90%) and there was a complete disappearance of the substantia nigra pars compacta [22].
• A patient with tremor associated with spasmodic dysphonia developed a marked exacerbation of her upper limb tremor whilst on co-careldopa (Sinemet CR) that improved when the drug was withdrawn [23].

Associations of MK 486 with other chemical compounds

• Food increased the levodopa bioavailability of Sinemet CR [10].
• Careful follow-up studies of patients treated with Madopar or Sinemet might provide further information about the possible physiological role of SSAO [24].
• Effects of tolcapone, a catechol-O-methyltransferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs [25].
• 4. Qualitative and quantitative evaluations of relevant neurologic functions showed small, but statistically significant improvements for rigidity, finger tapping speed and activities of daily living in patients during the Sinemet plus benztropine mesylate treatment period [26].
• Withdrawal of Sinemet therapy did not alter the TSH and Prl responses to TRH [27].

Gene context of MK 486

• COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients in levodopa/carbidopa (Sinemet) [28].
• Sinemet caused significantly greater placebo-corrected increases in GH and HVA during early as compared with late abstinence [29].
• During chronic treatment with L-dopa-carbidopa (Sinemet), the 24-h PRL level was 12.8 +/- 4.9 ng/ml (mean +/- SD) and there was persistence of augmented PRL secretion during sleep [30].
• The only significant difference in these parameters between the CR4 and standard Sinemet treatment periods in the entire group was a decrease in hours of dyskinesia per day [31].
• What to do when Sinemet fails: Part one [32].

Analytical, diagnostic and therapeutic context of MK 486

• This report discusses the results of a 14-week double-blind crossover study comparing the efficacy and tolerability of standard Sinemet with controlled-release Sinemet CR [33].
• Gastrointestinal transit of Sinemet CR in healthy volunteers [34].
• For most patients, titration will be required after the transition has been made from standard to controlled-release Sinemet [9].
• An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group [35].
• This double-blind study also suggested that elderly male patients with Parkinson's disease derived the greatest benefit from SINEMET CR [36].

References